Granted Patent
B2
US 12,473,338 · App. 17/133,782 · Granted Nov 18, 2025
Targeted engineered interferon and uses thereof
C07K14/555A61K47/60C07K14/56C07K16/2887C07K2317/22C07K2317/24C07K2317/569C07K2317/92C07K2319/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
Claims (9)
1 . A chimeric protein comprising:
(a) a variant consensus interferon comprising the amino acid sequence of SEQ ID NO: 2 and having a R150A mutation; and
(b) one or more targeting moieties, said targeting moieties comprising recognition domains comprising single-domain antibodies which specifically bind to target antigens or receptors; and
wherein the variant consensus interferon and the one or more targeting moieties are optionally connected with one or more linkers.
2 . The chimeric protein of claim 1 , wherein the variant consensus interferon is pegylated.
3 . The chimeric protein of claim 1 , wherein the targeting moiety binds an antigen or receptor on a tumor cell or an immune cell.
4 . The chimeric protein of claim 1 , wherein the single-domain antibody comprises a recombinant heavy-chain-only antibody (VHH) or a shark heavy-chain-only antibody (VNAR).
5 . The chimeric protein of claim 1 , wherein the recognition domain is a VHH.
6 . The chimeric protein of claim 1 , comprising two or more targeting moieties.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2023
From: KLEY, NIKOLAI
To: ORIONIS BIOSCIENCES, INC.
Reel/Frame 064324/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2023
From: TAVERNIER, JAN; ZABEAU, LENNART
To: ORIONIS BIOSCIENCES NV
Reel/Frame 064324/0076 →
CHANGE OF NAME
Recorded Jul 20, 2023
From: ORIONIS BIOSCIENCES NV
To: ORIONIS BIOSCIENCES BV
Reel/Frame 064349/0867 →
Continuity (3)
Continuation
16483109
Provisional Application
62454992
· Feb 6, 2017
References Cited (128)
US 5661009A
· Stabinksy
· 1997
[cited by applicant]
US 5914254A
· Mascarenhas et al.
· 1999
[cited by applicant]
US 8496921B2
· Wang
· 2013
[cited by applicant]
US 8980267B2
· Grewal et al.
· 2015
[cited by applicant]
US 9139634B2
· Morrison et al.
· 2015
[cited by applicant]
US 9492562B2
· Tavernier et al.
· 2016
[cited by applicant]
US 9534056B2
· Grewal et al.
· 2017
[cited by applicant]
US 9732135B2
· Tavernier et al.
· 2017
[cited by applicant]
US 9878014B2
· Tavernier et al.
· 2018
[cited by applicant]
US 9914759B2
· Tavernier et al.
· 2018
[cited by applicant]
US 9932409B2
· Tavernier et al.
· 2018
[cited by applicant]
US 20020193569A1
· Hanna
· 2002
[cited by applicant]
US 20110224407A1
· Langer et al.
· 2011
[cited by applicant]
US 20130183298A1
· Le et al.
· 2013
[cited by applicant]
US 20180186894A1
· Tavernier et al.
· 2018
[cited by applicant]
US 20180334489A1
· Tavernier et al.
· 2018
[cited by applicant]
US 20190202934A1
· Tavernier et al.
· 2019
[cited by applicant]
CN 1727470A
· 2006
[cited by applicant]
EP 0422697B1
· 1994
[cited by applicant]
EP 1739090A2
· 2007
[cited by applicant]
WO 1983004053A1
· 1983
[cited by applicant]
WO WO9102754A1
· 1991
[cited by applicant]
WO 2001010912A1
· 2001
[cited by applicant]
WO WO03033720A2
· 2003
[cited by applicant]
WO WO2006053883A1
· 2006
[cited by applicant]
WO WO2006115800A2
· 2006
[cited by applicant]
WO WO2007110231A2
· 2007
[cited by applicant]
WO WO2008014612A1
· 2008
[cited by applicant]
WO WO2008124086A2
· 2008
[cited by applicant]
WO WO2009003145A1
· 2008
[cited by applicant]
WO WO2009039409A1
· 2009
[cited by applicant]
WO 2009109129A1
· 2009
[cited by applicant]
WO WO2010036918A2
· 2010
[cited by applicant]
WO WO2010066740A1
· 2010
[cited by applicant]
WO WO2011020783A2
· 2011
[cited by applicant]
WO WO2011029870A1
· 2011
[cited by applicant]
WO WO2012170072A1
· 2012
[cited by applicant]
WO WO2013059885A2
· 2013
[cited by applicant]
WO WO2013107791A1
· 2013
[cited by applicant]
WO WO2013134138A1
· 2013
[cited by applicant]
WO 2014106492A2
· 2014
[cited by applicant]
WO 2014163684A1
· 2014
[cited by applicant]
WO WO2014194100A1
· 2014
[cited by examiner]
WO WO2015007520A1
· 2015
[cited by applicant]
WO WO2015007536A2
· 2015
[cited by applicant]
WO WO2015007542A1
· 2015
[cited by applicant]
WO WO2015007903A1
· 2015
[cited by applicant]
WO 2015168474A1
· 2015
[cited by applicant]
WO 2016065409A1
· 2016
[cited by applicant]
WO 2016201350A1
· 2016
[cited by applicant]
WO WO2017077382A1
· 2017
[cited by applicant]
WO WO2017134302A2
· 2017
[cited by applicant]
WO WO2017194782A2
· 2017
[cited by applicant]
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28) (Year: 2002).
[cited by examiner]
Brown et al. (J Immunol. May 1996;156(9):3285-91) (Year: 1996).
[cited by examiner]
Kulmanov et al (Bioinformatics, 34(4), 2018, 660-668) (Year: 2018).
[cited by examiner]
Bork (Genome Research, 2000, 10:398-400) (Year: 2000).
[cited by examiner]
Miosge (Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98) (Year: 2015).
[cited by examiner]
Lazar et al. (Mol. Cell. Biol., 8:1247-1252, 1988) (Year: 1988).
[cited by examiner]
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990) (Year: 1990).
[cited by examiner]
Skolnick et al (Trends Biotechnol. Jan. 2000;18(1):34-9) (Year: 2000).
[cited by examiner]
Acres, et al., “Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity,” Cancer Res., vol. 65, No. 20, pp. 9536-9546, 2005.
[cited by applicant]
Baba, et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-Directed CC Chemokine LARC,” The Journal of Biological Chemistry, vol. 272, No. 23, pp. 14893-14898, 1997.
[cited by applicant]
Barbara, et al., “Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF-α mutants,” EMBO Journal, vol. 13, No. 4, pp. 843-850, 1994.
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10, pp. 398-400, 2000.
[cited by applicant]
Bork, et al., “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics, vol. 12, pp. 125-427, 1996.
[cited by applicant]
Boschert, et al., “Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2,” Cellular Signalling 22 (7): 1…
[cited by applicant]
Bremer, et al., “Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists,” Cancer Res. 68: 597-604, 2008.
[cited by applicant]
Coulstock, et al., “Liver-Targeting of Interferon-Alpha with Tissue Specific Domain Antibodies,” Plos One, vol. 8, No. 2, pp. 1-11, 2013.
[cited by applicant]
De Bruyn, et al., “Antibody-Based Fusion Proteins to Target Death Receptors in Cancer,” Cancer Letters, vol. 332, pp. 175-183, 2013.
[cited by applicant]
Deffar, et al., “Nanobodies—The New Concept in Antibody Engineering,” African Journal of Biotechnology, vol. 8, No. 12, pp. 2645-2652, 2009.
[cited by applicant]
Dijkmans, et al., “Murine Interferon-γ Interleukin-1 Fusion Proteins Used as Antigens for the Generation of Hybridomas Producing Monoclonal Anti-Interleukin-1 Antibodies,” Cytokine, vol. 3, No. 2, pp. 134-140, 1991.
[cited by applicant]
Dimitrov, “Engineered CH2 Domains (Nanoantibodies),” mAbs, Landes Bioscience, vol. 1, No. 1, pp. 26-28, 2009.
[cited by applicant]
Frey, et al., “Antibody-Based Targeting of Interferon-Alpha to the Tumor Neovasculature: A Critical Evaluation,” ntegrative Biology, vol. 3, pp. 468-478, 2011.
[cited by applicant]
Garcin, et al., “High Efficiency cell-specific targeting of cytokine activity,” Nature Communications, vol. 5, No. 8, 9 pages, 2014.
[cited by applicant]
Garlanda, et al., “The Interleukin-1 Family: Back to the Future,” Immunity, 39 (6): pp. 1003-1018, Dec. 12, 2013.
[cited by applicant]
Holler, et al., “Two Adjacent Trimeric Fas Ligands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex,” Molecular and Cellular Biology, vol. 23, No. 4, pp. 1428-1440, 2003.
[cited by applicant]
Huang, et al., “A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-[alpha] Fusion Protein Induces HER2/Neu Signaling and Facilitates Repair of Injured Epithelia,” The Journal of Pharmacology and Experimental Therap…
[cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP17/61544, dated Oct. 20, 2017, 21 pages.
[cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP2017/065143, dated Jul. 11, 2017, 8 pages.
[cited by applicant]
Krippner-Heidenreich, et al., “Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity,” The Journal of Immunology, vol. 180, pp. 8176-8183, 2008.
[cited by applicant]
Loetscher, et al., “Human Tumor Necrosis Factor α (TNFα) Mutants with Exclusive Specificity for 55-kDA or 75- kDa TNF Receptors,” Journal of Biological Chemistry, American Society For Biochemistry and Molecular Biology,…
[cited by applicant]
Masci, et al., “New and Modified Interferon alfas: Preclinical and Clinical Data,” Current Oncology Reports, vol. 5, pp. 108-113, 2003.
[cited by applicant]
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction,” Edited by: Mertz et al., (Birkhauser, Boston), pp. 491-495…
[cited by applicant]
Pan, et al., “Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-a2 Generates Type I IFN Competitive Antagonists,” Biochemistry, vol. 47, pp. 12018-12027, 2008.
[cited by applicant]
Patris, et al., “Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination,” Talanta, 2014, vol. 130, pp. 164-170, 2014.
[cited by applicant]
Penafuerte, et al., “The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 fusion Protein Induces Potent Ex Vivo Natural Killer Cell Activation and Maturation,” Cancer Res, vol. 69, No…
[cited by applicant]
Piehler, et al., “New Structural and Functional Aspects of the Type I Inteferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface,” Journal of Biological Chemistry, vol. 275, No…
[cited by applicant]
Rafei, et al., “A MCP1 Fusokine with CCR2-Specific Tumoricidal Activity,” Molecular Cancer, vol. 10, No. 121, pp. 1-11, 2011.
[cited by applicant]
Rafei, et al., “An Engineered GM-CSF-CCL2 Fusokine Is A Potent Inhibitor of CCR2-Driven Inflammation as Demonstrated in a Murine Model of Inflammatory Arthritis,” The Journal of Immunology, vol. 183, pp. 1759-1766, 2009.
[cited by applicant]
Roisman, et al., “Structure of the Interferon-Receptor Complex Determined by Distant Constraints from Double Mutant Cycles and Flexible Docking,” PNAS, vol. 98, No. 23, pp. 13231-13236, 2001.
[cited by applicant]
Rovero, et al., “Insertion of the DNA for the 163-171 Peptide of IL 1 II Enables a DNA Vaccine Encoding p185
[cited by applicant]
Schutyser, et al., “The CC Chemokine CCL20 and its Receptor CCR6,” Cytokine & Growth Factor Reviews, vol. 14, pp. 409-426, 2003.
[cited by applicant]
Vaneycken, et al., “Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer”, The ASEB Journal, vol. 25, pp. 2433-2446, 2011.
[cited by applicant]
Weber, et al., “Single Amino Acid Changes that Render Human IFN-α2 Biologically Active on Mouse Cells,” The EMBO Journal, vol. 6, No. 3, pp. 591-598, 1987.
[cited by applicant]
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517, 1990.
[cited by applicant]
Wesolowski, et al., “Single Domain Antibodies: Promising Experimental and Therapeutic Tools in Infection and Immunity,” Med. Microbiol. Immunol., vol. 198, pp. 157-174, 2009.
[cited by applicant]
International Search Report & Written Opinion, PCT Appl. No. PCT/US18/16857, dated Apr. 24, 2018, 10 pages.
[cited by applicant]
Yan, et al., “Definition of the Interferon-α Receptor-binding Domain on the TYK2 Kinase,” The Journal of Biological Chemistry, vol. 273, No. 15, Feb. 13, 1998, 7 pages.
[cited by applicant]
Camacho, et al., “Structure of an Interleukin-1β Mutant With Reduced Bioactivity Shows Multiple Subtle Changes in Conformation That Affect Protein-Protein Recognition,” Biochemistry, vol. 32, No. 34, pp. 8749-8757, Aug.…
[cited by applicant]
Runkel, et al., “Systematic Mutational Mapping of Sites on Human Interferon-β-1a That Are Important for Receptor Binding and Functional Activity,” Biochemistry, vol. 39, No. 10, pp. 2538-2551, Mar. 14, 2000.
[cited by applicant]
Ebbinghaus, et al. “Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy,” International J. of Cancer vol. 116 No. 2, pp. 304-313 (2005).
[cited by applicant]
Cited By (1)